News
SPRC
4.270
+1.67%
0.070
Weekly Report: what happened at SPRC last week (0518-0522)?
Weekly Report · 2h ago
Weekly Report: what happened at SPRC last week (0511-0515)?
Weekly Report · 05/18 10:11
SciSparc Regains Conditional Nasdaq Compliance After Equity Shortfall
TipRanks · 05/11 12:29
SciSparc regains Nasdaq equity compliance, avoids delisting for now
PUBT · 05/11 12:04
Weekly Report: what happened at SPRC last week (0504-0508)?
Weekly Report · 05/11 10:09
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 05/04 12:06
Weekly Report: what happened at SPRC last week (0427-0501)?
Weekly Report · 05/04 10:07
Scisparc FY25 net loss widens 94% to USD 12.18 million
PUBT · 04/29 21:07
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 04/28 12:05
Weekly Report: what happened at SPRC last week (0420-0424)?
Weekly Report · 04/27 10:09
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 04/23 12:07
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 04/21 17:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 04/21 12:05
Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 04/21 08:43
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 04/20 21:05
Weekly Report: what happened at SPRC last week (0413-0417)?
Weekly Report · 04/20 10:05
Weekly Report: what happened at SPRC last week (0406-0410)?
Weekly Report · 04/13 10:09
Weekly Report: what happened at SPRC last week (0330-0403)?
Weekly Report · 04/06 10:09
Weekly Report: what happened at SPRC last week (0323-0327)?
Weekly Report · 03/30 10:09
Scisparc Director Alon Dayan Files Initial Beneficial Ownership Statement
Reuters · 03/23 20:01
More
Webull provides a variety of real-time SPRC stock news. You can receive the latest news about Scisparc through multiple platforms. This information may help you make smarter investment decisions.
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.